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Abstract
Escape from programmed cell death is a hallmark of cancer. In this study, we investigated the anti-apoptotic
mechanisms and explored the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in malignant pleural
mesothelioma (MPM), a lethal thoracic malignancy with an extreme dearth of treatment options. By implementing
integrated analysis of functional genomic data of MPM cells and quantitative proteomics of patients’ tumors, we
identified BCL-XL as an anti-apoptotic driver that is overexpressed and confers an oncogenic dependency in MPM.
MPM cells harboring genetic alterations that inactivate the NF2/LATS1/2 signaling are associated with increased
sensitivity to A-1155463, a BCL-XL-selective BH3 mimetic. Importantly, BCL-XL inhibition elicits protective autophagy,
and concomitant blockade of BCL-XL and autophagic machinery with A-1155463 and hydroxychloroquine (HCQ), the
US Food and Drug Administration (FDA)-approved autophagy inhibitor, synergistically enhances anti-MPM effects
in vitro and in vivo. Together, our work delineates the molecular basis underlying resistance to apoptosis and uncovers
an evasive mechanism that limits response to BH3 mimetics in MPM, suggesting a novel strategy to target this
aggressive disease.
Introduction
Malignant pleural mesothelioma (MPM) is a highly
aggressive malignancy that is etiologically associated
with asbestos exposure1,2. Despite the restriction of
asbestos use in most countries, the incidence of MPM is
still rising due in part to the long latency (around 40
years) of the interval from carcinogen exposure to tumor
onset3. There are no typical clinical symptoms of
mesothelioma in the early phase, and the majority of
patients (80%) are diagnosed at advanced stages asso-
ciated with extremely poor prognosis4. Previous studies
in MPM have revealed frequent oncogenic events
enabled by genetic alterations that inactivate tumor
suppressor genes, most often BRCA1 associated protein-
1 (BAP1), neurofibromatosis type 2 (NF2), large tumor
suppressor kinase 2 (LATS2), and cyclin-dependent
kinase inhibitor 2 A/2B (CDKN2A/2B), which, however,
have proven difficult to be therapeutically exploited2,5,6.
Further exacerbating the dilemma, platinum-based che-
motherapy, the current standard of care for inoperable
late-stage MPM, only marginally improves patient sur-
vival7. Hence, there is a pressing need to identify new
druggable targets in MPM and develop effective ther-
apeutic strategies for the daunting disease.
The NF2 tumor suppressor gene encodes Merlin
(Moesin-ezrin-radixin-like protein), which mediates
tumor suppression and contact-dependent inhibition by
repressing Hippo, mTORC1, RAS, EGFR, and FAK-Src
signaling pathways8. The Hippo signaling, an evolu-
tionally conserved pathway that regulates organ size and
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tissue homeostasis by restricting cell growth and pro-
moting apoptosis, is one of the best characterized Merlin/
NF2-regulated pathways9. Besides the mutation in NF2,
other components of the Hippo pathway, e.g., large tumor
suppressor kinase 1/2 (LATS1/2), are also frequently
inactivated in MPM patients6. Dysregulation of the Hippo
pathway constitutively activates Yes-associated protein
(YAP), a transcription regulator that promotes the tran-
scription of genes involved in cell proliferation and anti-
apoptosis by interaction with TEA/ATTS domain (TEAD)
transcription factors10.
Resistance to apoptosis, a critical barrier of tumor
development, is one of the most prominent hallmarks of
cancer11. Overexpression of pro-survival B-cell lymphoma
2 (BCL-2) family members (BCL-2, BCL-XL, MCL-1,
BCL-W,BCL-B, and BFL-1) is a key apoptosis evasion
mechanism that promotes tumor growth by keeping pro-
apoptosis effectors (BAX/BAK) in check11. By contrast, the
BCL-2 homology domain-3 (BH3)-only proteins (BAD,
BIM, BID, NOXA, PUMA, BIK, BMF, and HRK) induce
apoptosis by neutralizing the pro-survival BCL-2 pro-
teins12. As such, targeting anti-apoptotic regulators with
BH3 mimetics represents an attractive strategy for cancer
therapy13. Several BH3 mimetics, e.g., the BCL-2/BCL-XL/
BCL-W inhibitor ABT-263 (navitoclax), BCL-2–selective
inhibitor venetoclax (ABT-199), and BCL-XL–selective
inhibitor A-1155463, have showed promising clinical
activity14. In particular, venetoclax has been approved by
the US Food and Drug Administration (FDA) for the
treatment of chronic lymphocytic leukemia (CLL) with a
17p-deletion or TP53 mutation15. We and others have
reported that MPM cells can acquire anti-apoptotic
adaptation as a protective mechanism to evade onco-
genic stress and anticancer therapy16–18. In this study, we
systematically analyzed the cell survival dependency on
anti-apoptotic BCL-2 proteins and explored the potential
of specific BH3 mimetics as anti-MPM therapy.
Materials and methods
Cell culture and reagents
Human normal mesothelial cells (LP-9) was a gift from
Robert Kratzke (Masonic Cancer Center, University of
Minnesota, USA)19 and cultured in Medium 199 (Cat.
#M7528; Sigma-Aldrich) supplemented with 15% fetal
bovine serum (Cat. #10270-106; Life Technologies), 1%
penicillin/streptomycin solution (Cat. #P0781, Sigma-
Aldrich), 10 ng/ml of epidermal growth factor (Cat.
#E5036, Sigma-Aldrich), and 0.4 μg/ml hydrocortisone
(Cat. #07904, STEMCELL TECHNOLOGIES) at 37 °C
with 95% air/5% CO2. Human normal lung fibroblasts
(hFb16Lu;CCD-16Lu) and human MPM cell lines
(MESO-1, MESO-4, JL-1, H2452, MSTO-211H, and
H2052) were previously described18,20. All cells were
authenticated by short tandem repeat (STR) profiling and
regularly tested free of mycoplasma (Microsynth). A-
1155463 (Cat. #CS-5398), hydroxychloroquine (Cat.
#CS-8017), Venetoclax (Cat. #S8048), and ABT-263
(Cat. #S1001) were obtained from ChemScene and
SelleckChem, respectively. Bafilomycin A1 was provided
by K. Krempaska (Department for Biomedical Research,
University of Bern, Switzerland).
Cell viability and clonogenic survival assay
Cell viability was measured by acid phosphatase (APH)
assay as described18,20. Each data point was generated in
triplicate from three independent experiments (n= 3).
IC50 values were determined based on the best-fit curve
generated in GraphPad Prism [log (inhibitor) vs. nor-
malized response]. Combination Index (CI) was calcu-
lated by ComboSyn software21. CI < 1.0, synergism; CI=
1.0, additive effects, CI > 1.0, antagonism. Clonogenic
assay was done as described18,20. Briefly, cells seeded in
6-well plates (1000–2000 cells/well) were treated for 96 h
and cultured in the absence of drugs for 10–12 days
depending on growth rate. The resulting colonies
were stained with crystal violet (0.5% dissolved in 25%
methanol).
Immunoblotting and immunohistochemistry
Cell lysates were prepared and immunoblot analysis was
performed as described18,22. In brief, protein lysates were
resolved by SDS-PAGE (Cat. #4561033; Bio-Rad Labora-
tories) and transferred onto nitrocellulose membranes
(Cat. #170-4158; Bio-Rad). After incubation with blocking
buffer (Cat. #927-4000; Li-COR Biosciences) for 1 h at
room temperature, membranes were incubated with pri-
mary antibodies (BCL-XL: 1:1000, #2764; Cleaved Cas-
pase-7: 1:1000, #9491; LC3B: 1:500, #12741; Beclin-1:
1:1000, #3495; p62: 1:500, #5114; ATG5:1:1000, #12994;
Cell Signaling Technology) overnight at 4 °C. IRDye
680LT-conjugated goat anti-mouse IgG (Cat. #926-
68020) and IRDye 800CW-conjugated goat anti-rabbit
IgG (Cat. #926-32211) from Li-COR Biosciences were
used at 1:10000 dilutions. Signals of membrane-bound
secondary antibodies were visualized by the Odyssey
Infrared Imaging System (Li-COR Biosciences), followed
by quantification using Image J23.
Immunohistochemical study were performed as
described24. In brief, surgically removed xenograft tumors
(two tumors/group) were formalin-fixed, paraffin-
embedded (FFPE), and stained with hematoxylin and
eosin (H&E) using standard protocols. FFPE tissue blocks
were sectioned at 4 μm, deparaffinized, rehydrated, and
subsequently stained with appropriate antibodies (LC3B:
1:4000, #3868, Cell Signaling Technology; p62: 1:8000, #
WH0008878M1, Sigma; Cleaved Caspase-3: 1:200; #
9664, Cell Signaling Technology) using the automated
system BOND RX (Leica Biosystems)24. Visualization was
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performed using the Bond Polymer Refine Detection kit
(Leica Biosystems) as instructed by the manufacturer.
Images were acquired using PANNORAMIC® whole slide
scanners and processed using Case Viewer (3DHISTECH
Ltd.). The staining intensities of the whole slide (two
tumors/group) were quantified by QuPath software25.
Apoptosis assay
MPM cells were treated as specified in the figure legends.
After treatment, cells in the supernatant and adherent to
plates were collected, washed with PBS, and pooled before
suspended in 400 μl binding buffer and stained with the
Annexin V Apoptosis Detection Kit-FITC (Cat. #88-8005;
Fig. 1 (See legend on next page.)
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Thermo Fisher Scientific) according to the manufacturer’s
instructions. Flow cytometry analysis was performed on a
BD Biosciences LSRII flow cytometer.
Autophagic flux assay
The mCherry-eGFP-LC3B lentivirus was kindly pro-
vided by Mario P. Tschan (Institute of Pathology, Uni-
versity of Bern, Switzerland). Briefly, lentivirus was
transduced into cell lines followed by selection with
puromycin (1 μg/ml) for 3 days and various treatments.
Cells were then trypsinized and resuspended for flow
cytometry analysis of GFP and mCherry fluorescence
using a BD Biosciences LSRII flow cytometer. Data were
analyzed by FlowJo software and gates for populations
with low/intermediate/high mCherry/GFP ratio were set
according to previous studies26,27.
Small interfering RNA (siRNA) knockdown
Knockdown of BCL2L1 and ATG5 was achieved by
specific duplex siRNAs (BCL2L1 siRNA, 15 nM; ATG5
siRNA, 30 nM) purchased from Origene Technologies
(Cat. #SR319459 and SR322789). Transfection of siR-
NAs was performed with Lipofectamine 2000 (Cat.
#116628027, Invitrogen) according to the manu-
facturer’s instructions.
Animal experiments
Mouse experiments were conducted in accordance with
Institutional Animal Care and Ethical Committee-
approved animal guidelines and protocols. Experiments
were performed in 8-week-old male NSG (NOD-scid
IL2Rγnull) mice, with sample size not predetermined by
statistical method but rather based on preliminary experi-
ments. Group allocation was performed in a randomized
but not blinded manner. Suspensions of MESO-1 cells
mixed 1:1 with Matrigel (Cat. #356231; Corning) were
subcutaneously inoculated in the flanks (1 × 106 cells
/injection). One month after injection, mice were randomly
assigned to treatment groups (n= 5): (1) control; (2) A-
1155463 (5mg/kg, i.p., once daily); (3) HCQ (50mg/kg, i.p.,
once daily); (4) combination of A-1155463 and HCQ in the
abovementioned doses(Tumor size was measured by digital
caliper every two to three days. Tumor volume was cal-
culated as follows: (length x width x width)/2. Mice were
sacrificed at the end of 23-day treatment.
Public databases (TCGA, TCPA, CBioPortal, DepMap, GEO,
GSDC, and COSMIC)
Interrogation of publicly available dataset was per-
formed as we have described28. Specifically, transcriptome
profiling and reverse-phase protein array data of meso-
thelioma patients were obtained from the Cancer Genome
Atlas (TCGA), the Cancer Proteome Atlas (TCPA), and
the cBio Cancer Genomics Portal (CBioPortal)29,30. The
catalog of gene essentiality across MPM cell lines is
obtained from the Cancer Dependency Map Project
(DepMap)31. Transcriptomic data of MPM samples
(GSE2549) was downloaded from the Gene Expression
Omnibus(GEO)32. Genomics of Drug Sensitivity in Can-
cer (GDSC) and Catalog of Somatic Mutations in Cancer
(COSMIC) was used to extract transcriptomic data and
mutation status of MPM cell lines33,34.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 8 (GraphPad Software, Inc.). All samples that met
proper experimental conditions were included in the
analysis. Data represent biological replicates (n) and are
(see figure on previous page)
Fig. 1 BCL-XL is overexpressed and confers a survival dependency in MPM. A Genetic alterations and mRNA/protein expression of pro-survival
Bcl-2 family genes in the TCGA cohort of MPM patients (n= 87). Data were downloaded from the cBio Cancer Genomics Portal (CBioPortal). B, C The
dependency profile of pro-survival BCL-2 family genes (BCL2L1, BCL2L10, BCL2, BCL2A1, BCL2L2, and MCL1) in MPM cell lines based on genome-wide
CRISPR (NCIH28, NCIH2452, MPP89, NCIH2052, ISTMES2, MERO14, and MSTO-211H) or RNAi interference (MPP89, ACCMESO-1, NCI-H28, NCIH2452, NCI-
H2052, and JL-1) screens. Data were downloaded from The Cancer Dependency Map Project (DepMap) datasets: CRISPR (Avana) Public 19Q3 and
Combined RNAi (Broad, Novartis, Marcotte). D Volcano plot of transcriptomic comparison between patients’ MPM samples (n= 40) versus normal
pleural tissues (n= 5) (GSE2549). Genes significantly downregulated (adjusted p value <0.05) are shown in green and genes significantly upregulated
in red. The differentially expressed pro-survival Bcl-2 family genes are highlighted. E Immunoblots of BCL-XL in human normal fibroblasts (hFb16Lu),
normal mesothelial cells (LP-9), and MPM cells. Proteins lysates prepared from the cells were subjected to serial dilutions (100, 75, and 50%) for
immunoblot analysis (left). Densitometric analysis of the immunoblot (right) showed fold change of BCL-XL signal normalized against Actin and the
total protein, with the value of hFb16Lu cells set to 1. F BCL-XL protein level in TCGA pan-cancer cohort (n= 32). The expression profile was obtained
from The Cancer Proteome Atlas (TCPA). READ rectum adenocarcinoma, CHOL cholangiocarcinoma, MESO mesothelioma, COAD colon
adenocarcinoma, LUAD lung adenocarcinoma, SKCM skin cutaneous melanoma, LUSC lung squamous cell carcinoma, THCA thyroid carcinoma, UCEC
uterine corpus endometrial carcinoma, PAAD pancreatic adenocarcinoma, GBM glioblastoma multiforme, KICH kidney chromophobe, BLCA bladder
urothelial carcinoma, HNSC head and neck squamous cell carcinoma, PRAD prostate adenocarcinoma, OV ovarian serous cystadenocarcinoma, LGG
brain lower grade glioma, THYM thymoma, STAD stomach adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, TGCT testicular
germ cell tumors, BRCA breast invasive carcinoma, KICH kidney chromophobe, KIRP kidney renal papillary cell carcinoma, UVM uveal melanoma, UCS
uterine carcinosarcoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, ESCA esophageal carcinoma, PCPG
pheochromocytoma and paraganglioma, SARC sarcoma, LIHC liver hepatocellular carcinoma, ACC adrenocortical carcinoma.
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depicted as mean values ± s.d. or mean values ± SEM as
indicated in the figure legends. Comparison of mean
values was conducted with unpaired, two-tailed Student’s
t-test, one-way or two-way ANOVA as indicated in the
figure legends, P < 0.05 were considered statistically
significant.
Fig. 2 (See legend on next page.)
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Results
BCL-XL is deregulated and confers a survival dependency
in MPM
In the attempt to explore the potential of BH3 mimetics
as anti-MPM therapy, we investigated genetic status,
transcriptional expression, and dependency profile of the
pro-survival BCL-2 gene family (BCL2L1, BCL2L10,
BCL2, BCL2A1, BCL2L2, and MCL1) in MPM by inter-
rogating TCGA dataset and functional genomics that
determines genetic dependencies in cancers (DepMap;
https://depmap.org/portal/). The integrated molecular
characterization revealed that, of the anti-apoptotic genes,
BCL2L1 (encoding BCL-XL) is altered in a subset of MPM
patients (n= 87), by means of gene amplification and
mRNA overexpression (Fig. 1A) and MPM cells show the
greatest dependency on BCL2L1 for survival (Fig. 1B, C).
Consistently, BCL2L1 expression is significantly upregu-
lated in patients’ MPM compared with that in normal
pleural tissues (Fig. 1D). Our immunoblot analysis
revealed upregulated expression of BCL-XL in human
MPM cell lines compared with normal lung fibroblasts
(hFb16Lu) and mesothelial LP-9 cells (Supplementary
Fig. 1). Notably, a remarkably greater increase in BCL-XL
was observed in MPM cells compared with normal con-
trols when BCL-XL signal was normalized against
Actin (loading control) and the total protein (Fig. 1E).
Further supporting these observations, examination
of TCPA dataset, which provides quantitative proteomics
of patient-derived pan-cancers (n= 32), revealed that
MPM had the third highest level of BCL-XL (Fig. 1F).
These results indicate that anti-apoptotic BCL-XL is
deregulated in MPM at genetic, transcriptional, and
translational levels.
Next, we addressed whether BCL2L1 represents a
genetic vulnerability in MPM. BCL2L1 knockdown by
siRNAs caused significantly greater proliferative inhibi-
tion and apoptotic cell death in MPM cells (MESO-1,
MESO-4, JL-1, H2452, MSTO-211H, H28, and H2052)
than in LP-9 cells (Fig. 2A–D). Consistent with the
genetic results, A-1155463, a potent and highly selective
BCL-XL inhibitor
14, preferentially impaired MPM cells,
resulting in significantly greater growth inhibition in
MPM cells than in LP-9 cells (Fig. 2E). Importantly,
A-1155463 induced cleavage of caspase-7 (Fig. 2F) and a
dose-dependent increase of apoptotic cells in MESO-1, as
manifested by flow cytometry-based apoptotic analysis,
which showed that treatment with 62.5, 125, and 250 nm
A-1155463 resulted in 4-, 4.4-, and 5.4-fold increases in
apoptotic cells (Annexin V-positive) compared with
vehicle treatment (Fig. 2G). In contrast, A-1155463
treatment barely increased apoptosis compared with
vehicle control in LP-9 cells (Fig. 2F, G). Importantly, the
selective BCL-2 inhibitor Venetoclax failed to distinguish
malignant from normal mesothelial cells, leading to
almost equal effects on MPM and LP-9 cells (Supple-
mentary Fig. 2A). Taken together, these results reveal that
BCL-XL is highly deregulated and confers an oncogenic
dependency in MPM.
NF2/LAST1/2 mutations are associated with increased
sensitivity to BCL-XL inhibition in MPM
Next, we sought to identify potential biomarkers asso-
ciated with MPM response to BCL-XL inhibition in MPM.
As expected, the BCL-XL protein level was positively
correlated with the sensitivity to A-1155463 [negatively
with the IC50 (50% inhibitory concentration)] in MPM
cells (Fig. 3A, B).
It has been shown that cancer cells express high levels of
pro-apoptotic proteins that, however, are constrained via
heterodimerization by anti-apoptotic effectors during
tumorigeneis11,35. As a result, cancer cells can be con-
sidered to be ready to undergo apoptosis or “primed for
apoptosis”, highlighting the potential of BH3 mimetics in
the clinic36. To explore a possible link of BCL2L1 with
pro-apoptotic proteins in MPM, we examined a cohort of
MPM patients (n= 87) in TCGA, which revealed that
BCL2L1mRNA level was positively correlated with that of
several pro-apoptotic genes, e.g., BAX, BBC3, BIK, and
BAK1 (Fig. 3C). Consistent with this observation, MPM
cells that overexpress BCL-XL also have higher protein
(see figure on previous page)
Fig. 2 Genetic and pharmacological inhibition of BCL-XL preferentially impairs MPM cell proliferation. A-C Immunoblots (A) and
micrographic images (B) of LP-9 and MPM cells with siRNA-based BCL2L1 knockdown. Viable cells were counted 48 h post-transfection by trypan blue
dye exclusion (C). Data were presented as mean ± s.d. (n= 3). ****p < 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test. Scale bar:
50 μm. D Flow cytometry-based apoptotic assay of LP-9 and MESO-1 cells 48 h post-transfection with siRNAs. Shown on the right is fold change in
apoptotic cells (Annexin V-positive) induced by BCL2L1 knockdown (siBCL2L1) compared with control siRNA (siCtrl), with the value of the control
treatment set as 1. Data were presented as mean ± s.d. (n= 3), with a representative plot shown in the left. **p < 0.01 by two-way ANOVA with
Tukey’s multiple comparisons test. E Clonogenic assay of LP-9 and MPM cells treated with A-1155463 for 96 h and subsequently cultured in the
absence of the drug for additional 12 days. Quantification is shown underneath, with data presented as mean ± s.d. (n= 2). F Immunoblots of LP-9
and MESO-1 cells treated with A-1155463 for 24 h. G Flow cytometry-based apoptotic assay of LP-9 and MESO-1 cells after treatment with A-1155463
for 48 h. Shown on the right is fold change in apoptotic cells (Annexin V-positive) induced by treatment with A-1155463 treatment (BCL-XLi)
compared with vehicle control (0 nM), with the value of the control treatment set as 1. Data were presented as mean ± s.d. (n= 3), with a
representative plot shown in the left. ***p < 0.001 by two-way ANOVA with Tukey’s multiple comparisons test.
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levels of BAX (Supplementary Fig. 2B), suggesting that
BCL2L1-positive MPM tumors are “primed” to apoptosis
induction. By using a previously defined “primed for
apoptosis” gene signature, determined by transcriptional
expression of the pro-apoptotic genes (BAK1, BAX, BBC3,
BID, BIK, BOK, and HRK)37, we curated the “primed for
apoptosis” score of H2452, MSTO-211H, H28, and H2052
cells, chosen for the availability of their transcriptomic
Fig. 3 (See legend on next page.)
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data in the Catalog of Somatic Mutations in Cancer
(COSMIC). Our analysis revealed that MPM cells with
higher scores of the apoptosis gene signature were more
sensitive (lower IC50 values) to A-1155463 (Fig. 3D),
supporting the notion that expression of the pro-
apoptotic genes predicts BCL-XL inhibitor sensitivity.
Finally, we explored if recurrent genetic alterations in
MPM are associated with sensitivity to BCL-XL inhibition.
NF2/LATS1/2 loss of function (deletion, truncation, and
mutation) is frequent (38%) in MPM (Fig. 3E), which
downregulates YAP phosphorylation (YAP1_pS127) and
increases the activity of YAP oncoprotein (Fig. 3F). Con-
sistent with this observation, MPM patients with low
levels of YAP1_pS127 (increased YAP activity) were
associated with dismal prognosis (Fig. 3G) and MPM cells
harboring NF2/LATS1/2 mutations/deletions exhibited
increased sensitivity to A-1155463 (Fig. 3H). Supporting
this finding, examining the TCGA cohort of MPM
patients (n= 87) showed that NF2/LATS1/2-altered
tumors were characterized by an increased BCL2L1
expression and “primed for apoptosis” score (Fig. 3I).
Thus, BCL-XL protein expression, “primed for apopto-
sis” gene signature and genetic alterations in NF2/LATS1/
2 may serve as biomarkers to stratify MPM subsets that
likely benefit from BCL-XL targeted therapy.
BCL-XL inhibition elicits protective autophagy in MPM cells
Our observations that MPM cells show heterogeneous
responses to BCL-XL inhibition (Figs. 2, 3) suggest the
existence of resistance mechanisms. This prompted us to
explore the approaches to improve the efficacy of BCL-XL-
targeted therapy. Interrogation of TCPA dataset revealed
SQSTM1 (sequestosome 1; also termed p62) as the top
candidate that is significantly negatively correlated with
BCL-XL (Fig. 4A). p62 is a key component of autophagic
machinery functioning as a cargo adapter by physical
interaction with and subsequent delivery of autophagic
substrates to autophagosomes for degradation38,
suggesting a possible role for autophagy to protect MPM
cells from the stress elicited by BCL-XL inhibition. Sup-
porting our hypothesis, treatment with A-1155263 acutely
increased autophagic activity in MESO-1 cells, marked by
decreased p62, upregulated Beclin-1, and microtubule-
associated proteins 1A/1B light chain 3B (LC3B)-II
(Fig. 4B), whereby the conversion of cytosolic LC3B-I to
autophagosome-localized LC3B-II is proportional with
initiation of autophagy and therefore serves as a reliable
marker of autophagosomes38. Moreover, genetic (siRNAs)
and pharmacological (A-1155463) inhibition of BCL-XL
markedly increased the LC3B-II lapidated form, in parti-
cular the ratio of LC3B-II/Actin signal, compared with
vehicle controls at the basal level and in the presence of
Bafilomycin A1, an inhibitor of autophagosome-lysosome
fusion26,38, in a panel of MPM cells (Fig. 4C–F). In sharp
contrast, the same effects of BCL-XL inhibition were not
observed in LP-9 cells, as A-1155463 alone showed no
effect on the LC3B-II/Actin ratio (compared with vehicle
control), as did concomitant treatment with A-1155463
and Bafilomycin (compared with Bafilomycin alone)
(Supplementary Fig. 2C). Importantly, using the mCherry-
eGFP-LC3B fluorescence reporter26,27, we showed that
genetic and pharmacological inhibition of BCL-XL sig-
nificantly increased the mCherry:GFP fluorescence ratio, a
well-recognized measure of autophagic flux, in MPM cells
stably expressing mCherry-eGFP-LC3B (Fig. 4G, H), fur-
ther strengthening the notion that BCL-XL inhibition
increases autophagy.
SQSTM1/p62 deregulation (e.g., mRNA upregulation or
protein overexpression) occurred in a subset (9%) of
MPM patients (Fig. 4I). Although implications of
SQSTM1/p62 changes can be context-dependent and
deserve cautious interpretations, the steady state level of
p62 do reflect the autophagic status38 and it is widely
accepted that impaired autophagy contributes to initiation
and early development of cancer38,39. Indeed, previous
studies associated decreased p62 or high autophagy status
(see figure on previous page)
Fig. 3 NF2/LAST1/2 mutations are associated with increased sensitivity to BCL-XL inhibition in MPM cells. A Cell viability assay of LP-9 and a
panel of MPM cell lines treated with A-1155463 for 96 h. Data were presented as mean ± s.d. (n= 3). B Correlation analysis of BCL-XL protein levels
and the 50% inhibitory concentration (IC50) values of A-1155463 in MPM cell lines. C Volcano plot of Spearmans’ rank correlation coefficient between
gene expression of BCL2L1 and that of pro-apoptotic genes in patients’ MPM samples (n= 87). Data were downloaded from TCGA and subsequently
analyzed by R software (Cor.test function). D Correlation analysis of “primed” for apoptosis signature (based on the sum of gene expression of BAK1,
BAX, BBC3, BID, BIK, BOK, and HRK) and the IC50 of A-1155463 in MPM cell lines. Transcriptomic data of the indicated MPM cell lines were extracted
from Catalog of Somatic Mutations in Cancer (COSMIC). E Genetic status of NF2/LATS1/2 in TCGA cohort of MPM patients (n= 87). Data were
downloaded from cBioPortal. F Genetic alterations in NF2/LATS1/2 are associated with decreased protein level of YAP1_pS127. MPM patients (n= 61)
in a TCGA cohort were stratified according to NF2/LATS1/2 genetic status (altered or unaltered), with p value calculated by unpaired, two-tailed
Student’s t-test. G Kaplan–Meier curves showing overall survival (OS) of a TCGA cohort of MPM patients (n= 61) stratified by protein level of
YAP1_pS127 (high versus low). The p value is calculated by the log-rank test using R (version 3.4.3). H NF2/LATS1/2-mutant MPM cells showed
increased sensitivity to A-1155463 (IC50)
. MPM cells were grouped according to genetic status of NF2/LATS1/2, with p value calculated by unpaired,
two-tailed Student’s t-test. WT, no alterations in NF2/LATS1/2. I Genetic alterations in NF2/LATS1/2 are associated with increased BCL2L1 mRNA levels
and with a higher gene signature “primed” for apoptosis. MPM patients of a TCGA cohort (n= 87) were grouped according to NF2/LATS1/2 genetic
status in the tumors (altered or unaltered). p value was calculated by unpaired, two-tailed Student’s t-test.
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with better clinical outcomes in MPM and other
tumors40,41. Supporting this notion, high p62 levels pre-
dicted poorer prognosis in MPM patients, opposite to the
prognostic value of BCL-XL (Fig. 4J, Supplementary Fig.
S3A). Moreover, deregulation of SQSTM1/p62 and
BCL2L1 appeared mutually exclusive (Fig. 4I), reiterating
Fig. 4 (See legend on next page.)
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the reciprocal nature of p62-and BCL-XL-regulated pro-
cesses in MPM development. Together, these results
reveal that BCL-XL inhibition elicits autophagy, which
may act as a compensatory mechanism that counteracts
BCL-XL targeted therapy.
Concomitant blockage of BCL-XL and autophagy
synergistically enhances anti-MPM effects
To test this hypothesis that autophagy protects MPM
cells from the cytotoxicity of BCL-XL inhibition, MPM
cells were concomitantly treated with A-1155463 and the
autophagy inhibitor hydroxychloroquine (HCQ) across a
broad range of concentrations. While single agents sup-
pressed cell proliferation in a dose-dependent manner, A-
1155463 plus HCQ produced a strong synergy, leading to
significantly enhanced antiproliferative effects and apop-
totic cell death in a panel of MPM cells, including NF2/
LATS1/2-mutant and wild-type (Fig. 5A–E) but not in
human normal lung fibroblasts (Supplementary Fig. S3B).
The synergy also applied when HCQ was combined with
ABT-263, a pan-inhibitor against BCL-2, BCL-XL, and
BCL-W (Supplementary Fig. S3C–E).
To further explore the role of autophagy in MPM
response to BCL-XL inhibition, we knocked down
autophagy related 5 (ATG5), which encodes a key effector
protein (ATG5) involved in the initiation of pre-
autophagosome formation39. Genetic depletion of ATG5
in MPM cells significantly enhanced the antiproliferative
effects of BCL-XL inhibition (Fig. 5F, G), which is in line
with the results of pharmacological studies (Fig. 5A–D).
Thus, BCL-XL inhibition elicits protective autophagy and
combined blockage of BCL-XL and autophagy represents
a promising strategy to treat MPM.
BCL-XL inhibition combined with hydroxychloroquine
potently suppresses MPM growth in vivo
To extend the in vitro observations to in vivo, we eval-
uated efficacy of the combination treatment with A-1155463
and HCQ in MESO-1 xenografts. Whereas A-1155463
alone delayed tumor growth, the addition of HCQ pro-
foundly enhanced antitumor efficacy without obvious side
effects, i.e., body weight loss (Fig. 6A–D). Immunohisto-
chemical analysis demonstrated that tumors treated with
A-1155463 alone showed enhanced punctate staining of
LC3B (highlighted in insets) and reduced p62 compared
with the vehicle group (Fig. 6E), consistent with an increase
in the autophagic flux upon BCL-XL inhibition as we
showed in vitro. Importantly, the combination treatment
blunted A-1155463-elicited autophagy, accompanied by
increase in tumor cell apoptosis as indicated by the increase
in cleaved caspase-3 in the combination group compared
with single treatment (Fig. 6E). Immunoblots indicated that
drug combination of A-1155463 and HCQ increased p62
and cleaved caspase-7 compared with single agents alone
(Fig. 6F), further supporting the notion that combined
A-1155463 and HCQ suppresses autophagy and induces
apoptosis. Overall, these in vivo data validate a novel ther-
apeutic strategy by combined inhibition of BCL-XL and
autophagy to target MPM.
Discussion
In this study, we showed that MPM capitalizes on BCL-
XL for anti-apoptosis, and that NF2/LATS1/2-alterations
and pro-apoptotic gene expression are associated with
sensitivity to BCL-XL inhibition. We further revealed that
BCL-XL blockage elicited protective autophagy, such that
combined treatment with BCL-XL-selective BH3 mimetic
and clinically approved autophagy inhibitor yields strong
and synergistic anti-MPM effects in vitro and in vivo. Our
data suggest the therapeutic potential of targeting BCL-XL
alone for MPM subsets, and of co-targeting autophagy for
unselected MPM.
Apoptosis is regulated by pro- and anti-apoptotic BCL-2
proteins, which is invariably deregulated in cancer11,13. In
response to oncogenic or stress signals, malignant cells
overexpress anti-apoptotic proteins to dampen apoptosis
by sequestering pro-apoptotic activators35. In this sce-
nario, cancer cells are proposed to be “primed” for
(see figure on previous page)
Fig. 4 Genetic and pharmacological inhibition of BCL-XL increases autophagic flux in MPM cells. A, Volcano plot of Spearmans’ rank
correlation coefficient between BCL-XL and other tested proteins (n= 217). Proteomic data were downloaded from TCPA, and proteins significantly
(adjusted p value (or q value) <0.05) correlated with BCL-XL are highlighted. B Immunoblots of MESO-1 treated with A-1155463 for 24 h. C, D MPM
cells transiently transfected with BCL2L1-siRNAs (siBCL2L1) were treated (48 h post-transfection) with Bafilomycin (200 nM) or vehicle (DMSO) for 2 h
before subjected to immunoblots to assess autophagic flux. Protein quantification is shown in (D). Note the increase in LC3B-II/Actin ratio by BCL2L1
knockdown in the absence and presence of Bafilomycin. E, F MPM cells pre-treated with A-1155463 (1 μM) for 24 h were exposed to Bafilomycin
(200 nM) or vehicle (DMSO) for another 2 h before immunoblot analysis. Protein quantification is shown in (F). Note the increase in LC3B-II/Actin ratio
by A-1155463 treatment in the absence and presence of Bafilomycin. G, H MPM cells stably expressing mCherry-eGFP-LC3B were transfected with
BCL2L1-siRNA (siBCL2L1) or control siRNA for 48 h (G), or treated with A-1155463 (1 μM) or vehicle for 24 h (H) before analyzed by flow cytometry.
Data were presented as mean ± s.d. (n= 3). *p < 0.05, **p < 0.01, and ****p < 0.0001 by two-way ANOVA with Sidak’s multiple comparisons test of
control high versus experimental high (red). I Genetic status and mRNA/protein expression of BCL2L1 and SQSTM1 in a TCGA cohort of MPM patients
(n= 87). Data were downloaded from cBioPortal. J Kaplan–Meier analysis of MPM based on p62 protein level. TCGA cohort of MPM patients (n= 61)
with high- (in red) or low-p62 (in black) were stratified by optimal cutoff value of the p62 across all patients using the surv_cutpoint function in the R
“maxstat” package. The p value is calculated by the log-rank test using R (version 3.4.3).
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Fig. 5 Dual inhibition of BCL-XL and autophagy synergistically enhances antiproliferative effects and increases apoptosis. A, B Dose-
response curves (A) of MPM cells treated with A-1155463 and HCQ, alone or in combination, for 96 h. Combination index (CI) values (B) were
determined by the CompuSyn software. Data were shown as mean ± s.d. (n= 3). CI < 1.0, synergism; CI= 1.0, additive effects, CI > 1.0, antagonism.
C Clonogenic assay of MPM cells treated for 96 h with A-1155463 and HCQ, alone or in combination. Cells were cultured without the drug for
additional 12 days before crystal violet staining. Representative images of three independent experiments (n= 3) are shown. D Flow cytometry-
based apoptosis assay of MPM cells treated with A-1155463 and HCQ, alone or in combinations for 48 h. Data were presented as mean ± s.d. (n= 3),
with a representative plot shown in the left. *p < 0.05, ** p < 0.01, ***p < 0.005, and **** p < 0.001 by one-way ANOVA with Sidak’s multiple
comparisons test. E Immunoblots of MESO-1 cells treated with A-1155463 and HCQ, alone and in combination, for 24 h. F, G MPM cells transfected
with ATG5- or control siRNAs (siATG5, siCtrl) were analyzed (48 h post-transfection) by immunoblots (F) or treated with A-1155463 for another 24 h,
followed by quantification of viable cells (G). Data were shown as mean ± s.d. (n= 3). *p < 0.05 and ** p < 0.01 by unpaired t-test.
Xu et al. Cell Death and Disease          (2021) 12:406 Page 11 of 14
Official journal of the Cell Death Differentiation Association
Fig. 6 Hydroxychloroquine (HCQ) potentiates anti-MPM efficacy of A-1155463 in vivo. A Development of MESO-1 xenograft tumors treated
with the indicated drugs. Data were presented as mean ± SEM (n= 5). #p < 0.05, comparison between combination (A-1155463 plus HCQ)- versus A-
1155463-treated group by two-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, and **** p < 0.001, comparison between
combination- versus HCQ-treated group by two-way ANOVA with Tukey’s multiple comparisons test. B, C Tumor size (B) and weights (C) after the
treatment. Data were presented as mean ± SEM (n= 5). *p < 0.05 and ** p < 0.01 by unpaired t-test. D Mice body weights during the treatment. Data
were presented as mean ± SEM (n= 5). E Immunohistochemical staining for LC3B, p62, and cleaved caspase-3 of MESO-1 xenograft tumors after the
treatment. Quantification of p62 and cleaved Caspase-3 in the entire tissue sections were performed by QuPath. F Immunoblots for LC3B, p62, and
cleaved caspase-7 of MESO-1 xenograft tumors after the treatment. Protein quantification is shown to the right.
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apoptosis, as they accumulate sufficient amounts of the
pro-apoptotic activators36, which has engendered the
concept of cancer treatment by conquering or over-
whelming anti-apoptotic defenses, e.g., blockage of spe-
cific or multiple pro-survival proteins with BH3 mimetics
such as ABT-263 (navitoclax) and ABT-199 (veneto-
clax)12,42. In MPM, apoptosis suppression was reported to
be promoted by defects in core-apoptosis signaling43, and
the pro-apoptotic BH3 mimetic ABT-737 targeting BCL-
2/BCL-XL/BCL-W
44 and a pan-BCL-2 inhibitor (JY-1-
106) were active against MPM cells45,46. However, despite
the promising clinical activity of pan-BH3 mimetic drugs,
challenges still prevail due to intrinsic or/and acquired
resistance and on-target platelet toxicity14,47–49, necessi-
tating the need to dissect the survival dependency on
individual BCL-2 proteins and the use of selective BH3
mimetics in clinical development. We show here that
BCL-XL is a major survival dependency for MPM cells
and that the BCL-XL by selective BH3 mimetic demon-
strates therapeutic potential for subsets of MPM. Notably,
our data are consistent with earlier observations that
antagonizing BCL-XL by alternative strategies (e.g., anti-
sense oligonucleotides) suppresses MPM cell survival44,50
and with the finding of a very recent study51 published
amid the manuscript preparation of our work.
We showed for the first time that BCL-XL inhibition
elicits protective autophagy that limits the efficacy of
BCL-XL-selective BH3 mimetics. Autophagy and apop-
tosis constitute two important self-destructive processes
to maintain cellular homeostasis52, and there is a complex
reciprocal interplay53–55. Apoptosis activation can either
increase or decrease autophagy, but the underlying
mechanisms are controversial56. Recent studies have
reported that inhibition of pro-survival BCL-2 proteins with
BH3 mimetics could induce autophagy either by releasing
Beclin-1 from the BH3-binding groove of BCL-2/BCL-XL
or by BAX- and BAK1-mediated LC3B lipidation57–59. In
line with this notion, we revealed that targeting autop-
hagy with HCQ synergistically enhances the cytotoxic
effect of A-1155463, suggesting that this combination
may be a novel strategy for treating MPM. Notably and
in further support of our findings, a recent report pub-
lished amid the revision of this study showed that BCL-
XL is overexpressed and is an important pro-survival
protein in MPM cells60.
The lack of therapeutically exploitable mutations has
significantly hampered the development of targeted
therapies for MPM2,6, which, however, highlights the
importance to identify oncogenic dependencies rather
than specific driver mutations to combat MPM1. We have
systematically assessed the pro-survival BCL-2 proteins
for their contributions to anti-apoptosis in MPM cells,
which, to the best of our knowledge, has remained
incompletely defined. Overall, our work demonstrates the
therapeutic potential of BCL-XL-specific BH3 mimetics
in MPM, alone and in combination with the FDA-
approved HCQ.
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